Antiangiogenic treatment as a pre‐operative management of alveolar soft‐part sarcoma | Zendy

Conde Nuria | Zendy; Cruz Ofelia | Zendy; Albert Asteria | Zendy; Mora Jaume | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Antiangiogenic treatment as a pre‐operative management of alveolar soft‐part sarcoma

Author(s) -

Conde Nuria,

Cruz Ofelia,

Albert Asteria,

Mora Jaume

Publication year - 2011

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.23241

Subject(s) - alveolar soft part sarcoma , medicine , bevacizumab , tongue , soft tissue , sarcoma , blood cancer , surgery , soft tissue sarcoma , cancer , radiology , chemotherapy , pathology

Alveolar soft‐part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue. Pediatr Blood Cancer 2011; 57: 1071–1073. © 2011 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research